Mapping the Safety Profile of BiologicalsA Disproportionality Analysis Using the WHO Adverse Drug Reaction Database, VigiBase

被引：0

作者：

Thijs J. Giezen

Aukje K. Mantel-Teeuwisse

Ronald H.B. Meyboom

Sabine M.J.M. Straus

Hubert G.M. Leufkens

Toine C.G. Egberts

机构：

[1] Utrecht University,Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology

[2] Medicines Evaluation Board,WHO Collaborating Centre for International Drug Monitoring

[3] Uppsala Monitoring Centre,Department of Clinical Pharmacy

[4] University Medical Center Utrecht,undefined

来源：

Drug Safety | 2010年 / 33卷

关键词：

Infliximab; Etanercept; Adalimumab; Teriparatide; System Organ Class;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Background: Biologicals have specific characteristics, as compared with the small molecule drugs, and carry specific risks. Safety problems, for example infliximab and the risk for tuberculosis, have been identified via spontaneous reports of suspected adverse drug reactions (ADRs). However, in general there is limited data on the nature of spontaneously reported suspected ADRs for biologicals.

引用

页码：865 / 878

页数：13

共 50 条

[11] Drug-induced membranous nephropathy: Disproportionality analysis of the WHO safety database
Gerard, A. O.
Merino, D.
Cremoni, M.
Destere, A.
Teisseyre, M.
Esnault, V. L. M.
Sicard, A.
Seitz-Polski, B.
Drici, M. D.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 62 - 63
[12] Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database
Mota, Diogo
Rama, Tiago Azenha
Severo, Milton
Moreira, Andre
ALLERGY, 2021, 76 (10) : 3209 - 3211
[13] Statin-induced myasthenia: A disproportionality analysis of the WHO's VigiBase pharmacovigilance database
Gras-Champel, Valerie
Batteux, Benjamin
Masmoudi, Kamel
Liabeuf, Sophie
MUSCLE & NERVE, 2019, 60 (04) : 382 - 386
[14] Amyotrophic lateral sclerosis associated with statins. A disproportionality analysis of the WHO Program for International Drug Monitoring database (VigiBase)
Saint-Gerons, Diego Macias
Castro, Jose Luis
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (04) : 587 - 589
[15] Amyotrophic lateral sclerosis associated with statins. A disproportionality analysis of the WHO Program for International Drug Monitoring database (VigiBase)
Diego Macías Saint-Gerons
José Luis Castro
European Journal of Clinical Pharmacology, 2019, 75 : 587 - 589
[16] Profile of adverse drug reaction reports in South Africa: An analysis of VigiBase for the year 2017
Matlala, M. F.
Lubbe, M. S.
Steyn, H.
SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2023, 113 (06): : 1205 - 1212
[17] Disproportionality Analysis on Hypothyroidism With Roxadustat Using the Japanese Adverse Drug Event Database
Kouki, Yasunobu
Okada, Naoto
Saga, Kosuke
Ozaki, Masakazu
Saisyo, Atsuyuki
Kitahara, Takashi
JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (10): : 1141 - 1146
[18] Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database
Papazisis, G.
Siafis, S.
Cepatyte, D.
Giannis, D.
Stamoula, E.
Tzachanis, D.
Egberts, T.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (19) : 6003 - 6012
[19] Drug-induced minimal change disease: Disproportionality analysis of the WHO safety database
Gerard, A. O.
Merino, D.
Cremoni, M.
Destere, A.
Teisseyre, M.
Esnault, V. L. M.
Sicard, A.
Seitz-Polski, B.
Drici, M. D.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 42 - 42
[20] Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase™)
Khamisy-Farah, R.
Damiani, G.
Kong, J. D.
Wu, J.
Bragazzi, N. L.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (17) : 5448 - 5451

← 1 2 3 4 5 →